This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Online Surveillance of Treatment of Children With Growth Hormone Deficiency With ZOMACTON

This study has been completed.
Sponsor:
Collaborator:
Ferring Arzneimittel GmbH
Information provided by (Responsible Party):
Ferring Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT01365351
First received: June 1, 2011
Last updated: June 1, 2017
Last verified: June 2017
June 1, 2011
June 1, 2017
December 1, 2007
June 2016   (Final data collection date for primary outcome measure)
Efficacy of ZOMACTON [ Time Frame: Up to 5 years ]
measured by: body height, increase of body height per annum
Same as current
Complete list of historical versions of study NCT01365351 on ClinicalTrials.gov Archive Site
  • Efficacy measured by further parameters [ Time Frame: Up to 5 years ]
    measured by: weight, increase weight per annum sitting height, increase of sitting height per annum head circumference per annum bone age, increase of bone age per annum puberty development IGF-1, IGFBP-3 psychological cofactors
  • Safety of Zomacton and application device [ Time Frame: Up to 5 years ]
    measured by: local adverse reactions to the application device adverse events of Zomacton safety laboratory
Same as current
Not Provided
Not Provided
 
Online Surveillance of Treatment of Children With Growth Hormone Deficiency With ZOMACTON
Non-interventional Study With ZOMACTON in Children With Growth Hormone Deficiency
The purpose of this study is to investigate long-term treatment with Zomacton® for pituitary short stature in children with insufficient growth hormone production and/or short stature caused by Turner syndrome.
Not Provided
Observational
Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Clinics and private practices
Growth Hormone Deficiency
Other: Growth hormone
Drug given by prescription
Growth hormone
Children with growth hormone deficiency
Intervention: Other: Growth hormone
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
1034
June 2016
June 2016   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • therapeutic need according to SPC
  • written informed consent

Exclusion Criteria:

  • contraindications according to SPC
Sexes Eligible for Study: All
Child, Adult, Senior
No
Contact information is only displayed when the study is recruiting subjects
Germany
 
 
NCT01365351
ZOM/011207/03
No
Not Provided
Not Provided
Not Provided
Ferring Pharmaceuticals
Ferring Pharmaceuticals
Ferring Arzneimittel GmbH
Study Director: Clinical Development Support Ferring Pharmaceuticals
Ferring Pharmaceuticals
June 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP